| Phase 01 trial |
|
Phase 0
|
NCT06413095 |
Jun 2022 → Jun 2023 |
head and neck squamous cell carcinoma, soft tissue sarcoma |
Presage Biosciences |
Completed
|
No outcome recorded
|
| Phase 11 trial |
|
Phase 1
|
NCT03564691 |
Jul 2018 → Sep 2025 |
neoplasm |
Merck Sharp & Dohme LLC |
Completed
|
No outcome recorded
|
| Phase 1/26 trials |
|
Phase 1/2
|
NCT05319730 |
May 2023 → Jun 2027 expected |
esophageal squamous cell carcinoma |
Merck Sharp & Dohme LLC |
Recruiting
|
No outcome recorded
|
|
Phase 1/2
|
NCT05342636 |
Jul 2022 → Dec 2025 |
esophageal squamous cell carcinoma |
Merck Sharp & Dohme LLC |
Completed
|
No outcome recorded
|
|
Phase 1/2
|
NCT04938817 |
Aug 2021 → Dec 2029 expected |
small cell lung carcinoma |
Merck Sharp & Dohme LLC |
Active not recruiting
|
No outcome recorded
|
|
Phase 1/2
|
NCT04626518 |
Dec 2020 → Jul 2026 |
clear cell renal carcinoma |
Merck Sharp & Dohme LLC |
Completed
|
No outcome recorded
|
|
Phase 1/2
|
NCT04303169 |
Jun 2020 → Sep 2025 |
melanoma |
Merck Sharp & Dohme LLC |
Completed
|
No outcome recorded
|
|
Phase 1/2
|
NCT04165070 |
Dec 2019 → Feb 2032 expected |
non-small cell lung carcinoma |
Merck Sharp & Dohme LLC |
Recruiting
|
No outcome recorded
|
| Phase 25 trials · 1 missed |
|
Phase 2
|
NCT05446870 |
Jul 2022 → Dec 2023 |
ovarian serous adenocarcinoma |
Merck Sharp & Dohme LLC |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT04924101 |
Jul 2021 → Jun 2025 |
small cell lung carcinoma |
Merck Sharp & Dohme LLC |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT04895722 |
Jun 2021 → May 2025 overdue |
colorectal cancer |
Merck Sharp & Dohme LLC |
Active not recruiting
|
Missed primary
|
|
Phase 2
|
NCT04165096 |
Jan 2020 → Apr 2025 |
non-small cell lung carcinoma |
Merck Sharp & Dohme LLC |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT04165083 |
Dec 2019 → Oct 2025 |
non-small cell lung carcinoma |
Merck Sharp & Dohme LLC |
Completed
|
No outcome recorded
|